Skip to main content

CDMOs partnering in Covid-19 initiatives

13th May 2020

Submitted by:

Andrew Warmington

Several of the world’s major pharmaceutical CDMOS have recently made announcements relating to their participation in projects to develop treatment for the Covid-19 virus. Many involve chloroquines, in anticipation of their large-scale use.

Swedish-based Recipharm said that it has now secured supply of chloroquine phosphate, the API for its drug Klorokinfosfat RPH Pharma, and has commenced manufacture of the product. It has also begun the development of a new product with hydroxychloroquine sulfate (HCQ) as the API This followed reports that chloroquine phosphate may be part of the therapy for COVID-19 patients.

Although chloroquine and HCQ are not yet indicated for Covid-19, the company said, many clinical studies involving them are in progress and it has therefore “put substantial focus on having stock available in the event that demand increases upon positive clinical data and new guidelines”.

Meanwhile in the UK, Sterling Pharma Solutions has also begun producing HCQ and will manufacture the API for a finished product being manufactured and supplied by Accord Healthcare. This will re-establish UK production in the event of successful trials. Sterling has already bought over 50 tonnes of the key raw materials, equating to roughly 60 million finished tablets of HCQ.

Accord expects to supply about 50 million tablets/month from its facility in Barnstable. “It is vital to proactively establish a strong supply route ahead of time,” said Sterling CEO Kevin Cook.

Similarly in the US, AMRI is increasing HCQ production at its site in Rensselaer, New York state, in anticipation of increasing demand. The company said that its Type II DMF for HCQ is available to support increased need and noted that the FDA has authorised emergency use of HCQ to treat some hospitalized patients with Covid-19.

Earlier, in Japan, Kaneka agreed to supply API for the anti-influenza drug, Avigan Tablet (favipiravir) to Fujifilm. This is expected to be effective against Covid-19 and the Japanese government is increasing its stockpiles in order to supply it to up to 2 million people. Fujifilm is therefore ramping up tablet production.

Finally in the US in April, Alcami formed a partnership to supply API for clinical trials of Eagle Pharmaceuticals’ Ryanodex (dantrolene sodium) for injectable suspension, which inhibited the growth of the virus in in vitro tests. Eagle has applied to the FDA for an IND for a Phase II clinical trial and has requested an expedited review. The drug is already approved for the treatment of malignant hyperthermia.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington